Biodesix Inc
NASDAQ:BDSX

Watchlist Manager
Biodesix Inc Logo
Biodesix Inc
NASDAQ:BDSX
Watchlist
Price: 1.28 USD 6.67% Market Closed
Market Cap: 186.2m USD
Have any thoughts about
Biodesix Inc?
Write Note

Biodesix Inc
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biodesix Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Biodesix Inc
NASDAQ:BDSX
Total Other Income
-$1.3m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
Total Other Income
-$61.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Total Other Income
$10m
CAGR 3-Years
-70%
CAGR 5-Years
27%
CAGR 10-Years
9%
CVS Health Corp
NYSE:CVS
Total Other Income
$96m
CAGR 3-Years
-21%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Cigna Corp
NYSE:CI
Total Other Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Total Other Income
$84.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
21%
No Stocks Found

Biodesix Inc
Glance View

Market Cap
186.2m USD
Industry
Health Care

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.

BDSX Intrinsic Value
1.93 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Biodesix Inc's Total Other Income?
Total Other Income
-1.3m USD

Based on the financial report for Dec 31, 2023, Biodesix Inc's Total Other Income amounts to -1.3m USD.

What is Biodesix Inc's Total Other Income growth rate?
Total Other Income CAGR 3Y
-15%

The average annual Total Other Income growth rates for Biodesix Inc have been -15% over the past three years .

Back to Top